Digene to develop DNA test for herpes:
This article was originally published in Clinica
Digene has received a grant from the US National Institutes of Health to develop a DNA test for the herpes simplex virus (HSV) based on the company's Hybrid Capture II technology. The company plans to use the $750,000 award to develop a simple, sensitive and cost-effective test to improve detection, screening and monitoring of patients with HSV Types 1 and 2 infection. The Beltsville, Maryland-based company estimated that three to five million HSV tests are performed annually in the US, while six to 10 million are carried out worldwide.
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.
With less than one hundred days left before the European Union Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss growing concerns by medtech industry members that they may not be ready in time to comply with these regulations and may inadvertently go afoul of the new regulations.